Navigation Links
Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
Date:3/15/2008

t the entire one-year treatment period. Significantly fewer serious adverse events were reported in the Dimebon group than in the placebo group at 12 months (p=0.03).

Medivation is planning to initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in mild-to-moderate Alzheimer's disease in the second quarter of 2008 with the goal of completing the trial and applying for U.S. and European marketing approval in 2010. The Company is also evaluating Dimebon in an ongoing Phase 2 clinical trial in mild-to-moderate Huntington's disease. Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's and Huntington's diseases, making it a potential treatment for these and other neurodegenerative diseases.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significan
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
3. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
4. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
5. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
6. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Young ... supplies and equipment, today announced the acquisition of ... Products Laboratories, Inc. ("MPL PDCMD"). MPL PDCMD manufactures ... in preventive and restorative dental procedures. ... of our business in attractive, high-growth segments," said ...
(Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... quarter and six months ended June 30, 2015. ... ITP are progressing and we continue to expect results ... , president and chief executive officer of Rigel. "We ... clinical programs, including evaluating fostamatinib for new treatment indications, ...
(Date:8/4/2015)... , Aug. 4, 2015  Dr. Keesha ... the potential FDA approval of flibanserin, or what ... and the treatment of decreased female sexual desire ... many root causes and addressing libido as a ... ...
Breaking Medicine Technology:Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ) ... biotechnology research and development outsourcing company, today announced that ... growing capacity needs of one of its largest customers, ... it has signed a multi-year extension of its contract ...
... 10, 2012 Reportlinker.com announces that ... available in its catalogue: ... Market Outlook in BRICS (Brazil, Russia, ... http://www.reportlinker.com/p0750215/Magnetic-Resonance-Imaging-MRI-Systems-Market-Outlook-in-BRICS-Brazil-Russia-India-China-South-Africa-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ...
Cached Medicine Technology:ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline 2ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline 3Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 2Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 3Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 4Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 5Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 6Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 7Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 8Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 9Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 10Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 11Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 12Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 13Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 14Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 15Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 16Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 17
(Date:8/4/2015)... ... August 05, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... nation’s leading networking organization exclusively for professional women, boasting more than 700,000 members ...
(Date:8/4/2015)... ... August 05, 2015 , ... The Journal of ... Obesity ”. , As corresponding author Professor Akiko Okifuji says “Both obesity and chronic ... it is not to say that one causes the other. Rather, there appear to ...
(Date:8/4/2015)... ... August 04, 2015 , ... assistPoint Partners, ... innovation to consolidate oncology patient assistance programs. Through a secure web portal, assistPoint ... assistPoint is an enterprise level, cloud-based application and workflow solution. This provides cancer ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Bayco Products, Inc. ... enough to fit, for example, on hard hats that have a flip-up face shield. ... allows users to work without having to remove their headlamp when raising or ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3
... June 19 The telephone number for the suicide prevention ... being carried on more than 21,000 city buses in 124 ... 1, 2009. , , The advertisements carry a message ... are undergoing an emotional crisis. , , "We ...
... Move comes after FDA reports 66 cases of E. ... (HealthDay News) -- U.S. health officials are warning consumers not ... because of the risk of E. coli contamination. ... Nestlé USA said Friday that it was voluntarily recalling its ...
... autistic child filed a motion in federal court today to confirm ... Michigan. The family alleged in the suit that the insurer ... disorder (ASD), on the baseless ground that the care was "experimental." ... reached at a court-ordered conference on Wednesday, June 17, 2009, Blue ...
... comes after FDA reports 66 cases of E. coli ... News) -- U.S. health officials are warning consumers not to ... of the risk of E. coli contamination. , ... USA said Friday that it was voluntarily recalling its Toll ...
... High Clinical Cure Rates in Adult Patients Hospitalized for Moderate ... 2009 Forest Laboratories, Inc. (NYSE: FRX ) ... studies of ceftaroline for the treatment of community-acquired bacterial pneumonia ... trials (FOCUS I and II) demonstrate that ceftaroline met the ...
... former CEO of FedEx Kinko,s, has been re-elected Chairman of the ... today. , , "Ken May is a strong and effective ... Jennifer L. Howse, President of the March of Dimes. "We look ... of giving every baby a healthy start in life." , ...
Cached Medicine News:Health News:Nestlé Recalls Cookie Dough Products 2Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 2Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 3Health News:Nestlé Recalls Raw Cookie Dough Products 2Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 2Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 3Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 4Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 5
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... Access ...unlike any trocar system you've ever ... actually four systems in one designed ... adaptive to all of your needs., ... or dilating tip styles, OnePort™ can effectively ...
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
... of Surgical Access ...unlike any trocar system ... system is actually four systems in one ... and clinically adaptive to all of your ... and bladed or dilating tip styles, OnePort™ ...
Medicine Products: